Valneva (NASDAQ:VALN) and Pfizer (NYSE:PFE) have announced favorable results from their VLA15-221 Phase 2 study of a Lyme disease vaccine candidate, VLA15.
The study, which involved booster doses, demonstrated a significant immune response and a good safety profile in pediatric, adolescent, and adult populations.
Notably, the seroconversion rates were above 90% for all six OspA serotypes.
"We are encouraged by these data, which support the potential benefit of booster doses across all examined age groups," stated Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva.
Annaliesa Anderson, Ph.D., Senior Vice President and Head of Vaccine Research and Development at Pfizer, also expressed optimism, stating, "These data from the VLA15-221 study are an important step towards a potential vaccine that could help prevent Lyme disease and ease the burden of acute, severe and sometimes persistent consequences."
Pfizer and Valneva plan to submit regulatory applications in 2026, contingent on successful Phase 3 trial outcomes.
Following the announcement, Valnava's share price remained steady at $7.32.